日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study

鲁索替尼联合一线新辅助治疗晚期卵巢癌的I期和随机II期研究:NRG肿瘤协作组研究

Landen, Charles N; Buckanovich, Ronald J; Sill, Michael W; Mannel, Robert S; Walker, Joan L; DiSilvestro, Paul A; Mathews, Cara A; Mutch, David G; Hernandez, Marcia L; Martin, Lainie P; Bishop, Erin; Gill, Sarah E; Gordinier, Mary E; Burger, Robert A; Aghajanian, Carol; Liu, Joyce F; Moore, Kathleen N; Bookman, Michael A

Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study

一项针对晚期卵巢癌/输卵管癌/腹膜癌女性患者的维持性紫杉烷类药物治疗与监测的III期随机试验:妇科肿瘤协作组0212:NRG肿瘤学研究

Copeland, Larry J; Brady, Mark F; Burger, Robert A; Rodgers, William H; Huang, Helen Q; Cella, David; O'Malley, David M; Street, Daron G; Tewari, Krishnansu S; Bender, David P; Morris, Robert T; Lowery, William J; Miller, David S; Dewdney, Summer B; Spirtos, Nick M; Lele, Shashikant B; Guntupalli, Saketh; Ueland, Frederick R; Glaser, Gretchen E; Mannel, Robert S; DiSaia, Philip J

Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study

基于肿瘤内在化疗敏感性识别一线贝伐单抗治疗中获益最大的卵巢癌患者(KELIM):GOG-0218 验证研究

You, Benoit; Purdy, Christopher; Copeland, Larry J; Swisher, Elizabeth M; Bookman, Michael A; Fleming, Gini; Coleman, Robert; Randall, Leslie M; Tewari, Krishnansu S; Monk, Bradley J; Mannel, Robert S; Walker, Joan L; Cappuccini, Fabio; Cohn, David; Muzaffar, Mahvish; Mutch, David; Wahner-Hendrickson, Andrea; Martin, Lainie; Colomban, Olivier; Burger, Robert A

Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study

种族和年龄对晚期上皮性卵巢癌预后意义的研究:一项NRG肿瘤/妇科肿瘤组研究

duPont, Nefertiti C; Enserro, Danielle; Brady, Mark F; Moxley, Katherine; Walker, Joan L; Cosgrove, Casey; Bixel, Kristin; Tewari, Krishnansu S; Thaker, Premal; Wahner Hendrickson, Andrea E; Rubin, Stephen; Fujiwara, Keiichi; Casey, A Catherine; Soper, John; Burger, Robert A; Monk, Bradley J

Patterns of adjuvant treatment and survival outcomes in stage I uterine carcinosarcoma

I期子宫癌肉瘤辅助治疗模式及生存结果

Cory, Lori; Brensinger, Colleen; Burger, Robert A; Giuntoli, Robert L 2nd; Morgan, Mark A; Latif, Nawar; Lin, Lilie L; Ko, Emily M

Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival

生活质量和不良事件:卵巢癌长期生存的预后关系

Wenzel, Lari; Osann, Kathryn; McKinney, Chelsea; Cella, David; Fulci, Giulia; Scroggins, Mary J; Lankes, Heather A; Wang, Victoria; Nephew, Kenneth P; Maxwell, George L; Mok, Samuel C; Conrads, Thomas P; Miller, Austin; Mannel, Robert S; Gray, Heidi J; Hanjani, Parviz; Huh, Warner K; Spirtos, Nick; Leitao, Mario M; Glaser, Gretchen; Sharma, Sudarshan K; Santin, Alessandro D; Sperduto, Paul; Lele, Shashikant B; Burger, Robert A; Monk, Bradley J; Birrer, Michael

Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC)

影像学和血浆生物标志物相关性预测上皮性卵巢癌(EOC)对贝伐单抗的反应

Buechel, Megan E; Enserro, Danielle; Burger, Robert A; Brady, Mark F; Wade, Katrina; Secord, Angeles Alvarez; Nixon, Andrew B; Mirniaharikandehei, Seyedehnafiseh; Liu, Hong; Zheng, Bin; O'Malley, David M; Gray, Heidi; Tewari, Krishnansu S; Mannel, Robert S; Birrer, Michael J; Moore, Kathleen N

Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study

一项随机 II 期试验比较了纳武利尤单抗与纳武利尤单抗联合伊匹木单抗治疗复发性或持续性卵巢癌的疗效:NRG 肿瘤学研究

Zamarin, Dmitriy; Burger, Robert A; Sill, Michael W; Powell, Daniel J Jr; Lankes, Heather A; Feldman, Michael D; Zivanovic, Oliver; Gunderson, Camille; Ko, Emily; Mathews, Cara; Sharma, Sudarshan; Hagemann, Andrea R; Khleif, Samir; Aghajanian, Carol

Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218

预测性血液生物标志物在接受卡铂和紫杉醇联合或不联合贝伐单抗治疗的上皮性卵巢癌患者中的应用:GOG-0218 研究结果

Alvarez Secord, Angeles; Bell Burdett, Kirsten; Owzar, Kouros; Tritchler, David; Sibley, Alexander B; Liu, Yingmiao; Starr, Mark D; Brady, J Chris; Lankes, Heather A; Hurwitz, Herbert I; Mannel, Robert S; Tewari, Krishnansu S; O'Malley, David M; Gray, Heidi; Bakkum-Gamez, Jamie N; Fujiwara, Keiichi; Boente, Matthew; Deng, Wei; Burger, Robert A; Birrer, Michael J; Nixon, Andrew B

BRCA Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer

BRCA突变、同源DNA修复缺陷、肿瘤突变负荷以及复发性卵巢癌对免疫检查点抑制剂的反应

Liu, Ying L; Selenica, Pier; Zhou, Qin; Iasonos, Alexia; Callahan, Margaret; Feit, Noah Z; Boland, Julia; Vazquez-Garcia, Ignacio; Mandelker, Diana; Zehir, Ahmet; Burger, Robert A; Powell, Daniel J Jr; Friedman, Claire; Cadoo, Karen; Grisham, Rachel; Konner, Jason A; O'Cearbhaill, Roisin E; Aghajanian, Carol; Reis-Filho, Jorge S; Weigelt, Britta; Zamarin, Dmitriy